Thrombosis in pediatric patients with leukemia

Area of Science:

• Pediatric Oncology
• Hematology
• Thrombosis Research

Background:

• Acute lymphoblastic leukemia (ALL) is the most common childhood cancer.
• Pediatric ALL is strongly associated with an increased risk of thromboembolism.
• Venous thromboembolism (VTE) incidence in pediatric ALL ranges from 5% (symptomatic) to 30-70% (asymptomatic).

Purpose of the Study:

• To review the epidemiology, etiology, and risk factors of VTE in pediatric ALL.
• To discuss current evidence regarding VTE diagnosis and treatment in this population.
• To highlight the lack of established guidelines for VTE prevention and management.

Main Methods:

• Literature review of existing studies on VTE in pediatric ALL.
• Analysis of multifactorial etiologies including chemotherapy, central venous lines, and inherited thrombophilia.
• Examination of common sites for thrombotic events, such as upper venous system and CNS.

Main Results:

• VTE is a significant complication in pediatric ALL, with increasing diagnosis rates.
• Chemotherapy protocols (e.g., l-Asparaginase), central venous lines (CVL), and inherited thrombophilia are key risk factors.
• Symptomatic VTE commonly affects the upper venous system and central nervous system (CNS).

Conclusions:

• VTE poses a substantial risk to children with ALL.
• Multifactorial etiology necessitates a comprehensive understanding of risk.
• Further prospective studies are crucial for developing evidence-based guidelines for VTE management in pediatric ALL.